McKesson Bets $2.25 Billion More on Oncology With Precision Medicine Buy

finance.yahoo.com · 2026-09-06

Reuters reported that McKesson Corporation (NYSE:MCK) said it would buy privately held Precision Medicine Group in a deal valued at about $2.25 billion as part of a “years-long effort to strengthen its higher-growth businesses.” McKesson has been reshaping its portfolio by exiting non-core assets and streamlining its operations while investing in businesses such as oncology […]

TickrTrends take: McKesson's 2 billion dollar investment in oncology and precision medicine represents a significant capital deployment that reflects management's strategic priorities in a high-growth therapeutic area. Given TickrTrends' fairly valued assessment, investors should monitor how effectively the company deploys this capital and whether the acquisition generates returns that justify the spending relative to the company's current valuation multiple. The healthcare sector move positions McKesson to capture growth in oncology services, but the valuation impact will depend on the timing of revenue contribution and margin accretion from the acquired assets.

Read the full story at finance.yahoo.com →